Cargando…

Who Should Not Be Surveilled for HCC Development after Successful Therapy with DAAS in Advanced Chronic Hepatitis C? Results of a Long-Term Prospective Study

Background and aims: The identification of patients with Hepatitis C Virus (HCV)-positive advanced chronic liver disease (aCLD) successfully treated by Direct Acting Antiviral Agents (DAAs) who really benefit from Hepatocellular Carcinoma (HCC) surveillance programs is still a matter of debate. We p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ciancio, Alessia, Ribaldone, Davide Giuseppe, Spertino, Matteo, Risso, Alessandra, Ferrarotti, Debora, Caviglia, Gian Paolo, Carucci, Patrizia, Gaia, Silvia, Rolle, Emanuela, Sacco, Marco, Saracco, Giorgio Maria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856119/ https://www.ncbi.nlm.nih.gov/pubmed/36672675 http://dx.doi.org/10.3390/biomedicines11010166

Ejemplares similares

Effect of COVID-19 Pandemic on Hepatocellular Carcinoma Diagnosis: Results from a Tertiary Care Center in North-West Italy
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2022)

The Clinical Role of Serum Epidermal Growth Factor Receptor 3 in Hepatitis C Virus-Infected Patients with Early Hepatocellular Carcinoma
por: Caviglia, Gian Paolo, et al.
Publicado: (2021)

Alpha-Fetoprotein, Protein Induced by Vitamin K Absence or Antagonist II and Glypican-3 for the Detection and Prediction of Hepatocellular Carcinoma in Patients with Cirrhosis of Viral Etiology
por: Caviglia, Gian Paolo, et al.
Publicado: (2020)

Prognostic Role of Serum Cytokeratin-19 Fragment (CYFRA 21-1) in Patients with Hepatocellular Carcinoma
por: Caviglia, Gian Paolo, et al.
Publicado: (2020)

Identification of the Best Cut-Off Value of PIVKA-II for the Surveillance of Patients at Risk of Hepatocellular Carcinoma Development
por: Caviglia, Gian Paolo, et al.
Publicado: (2023)

Liver Cancer-Specific Isoform of Serine Protease Inhibitor Kazal for the Detection of Hepatocellular Carcinoma: Results from a Pilot Study in Patients with Dysmetabolic Liver Disease
por: Caviglia, Gian Paolo, et al.
Publicado: (2022)

Higher Efficiency of Percutaneous Microwave (MWA) Than Radiofrequency Ablation (RFA) in Achieving Complete Response in Cirrhotic Patients with Early Hepatocellular Carcinoma
por: Gaia, Silvia, et al.
Publicado: (2021)

Biomarkers of Oncogenesis, Adipose Tissue Dysfunction and Systemic Inflammation for the Detection of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease
por: Caviglia, Gian Paolo, et al.
Publicado: (2021)

Screening and surveillance of oesophageal varices in patients with HCV‐positive liver cirrhosis successfully treated by direct‐acting antiviral agents
por: Ciancio, Alessia, et al.
Publicado: (2022)

HCC occurrence after DAA treatments: molecular tools to assess the post-treatment risk and surveillance
por: Pascut, Devis, et al.
Publicado: (2020)

Clinical Application of Droplet Digital PCR for Hepatitis Delta Virus Quantification
por: Olivero, Antonella, et al.
Publicado: (2022)

Inflammatory Bowel Disease: Emerging Therapies and Future Treatment Strategies
por: Bretto, Elisabetta, et al.
Publicado: (2023)

The Effect of Viral Clearance Achieved by Direct-Acting Antiviral Agents on Hepatitis C Virus Positive Patients with Type 2 Diabetes Mellitus: A Word of Caution after the Initial Enthusiasm
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2020)

Should we undertake surveillance for HCC in patients with MAFLD?
por: Norero, Blanca, et al.
Publicado: (2023)

Oral Zinc Supplementation Decreases the Risk of HCC Development in Patients With HCV Eradicated by DAA
por: Hosui, Atsushi, et al.
Publicado: (2021)

Long-Term Hepatocellular Carcinoma Development and Predictive Ability of Non-Invasive Scoring Systems in Patients with HCV-Related Cirrhosis Treated with Direct-Acting Antivirals
por: Caviglia, Gian Paolo, et al.
Publicado: (2022)

Timing of DAA Initiation After Curative Treatment and Its Relationship with the Recurrence of HCV-Related HCC
por: Gao, Xiuzhu, et al.
Publicado: (2020)

Incidence of Prostate Cancer in Inflammatory Bowel Disease: A Meta-Analysis
por: Carli, Edoardo, et al.
Publicado: (2020)

A Retrospective Experience of Helicobacter pylori Histology in a Large Sample of Subjects in Northern Italy
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2021)

APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation
por: Kanda, Tatsuo, et al.
Publicado: (2019)

HCC in the Era of Direct-Acting Antiviral Agents (DAAs): Surgical and Other Curative or Palliative Strategies in the Elderly
por: Brozzetti, Stefania, et al.
Publicado: (2021)

Risk Factors of Urothelial Cancer in Inflammatory Bowel Disease
por: Caviglia, Gian Paolo, et al.
Publicado: (2021)

Usefulness of a Hepatitis B Surface Antigen-Based Model for the Prediction of Functional Cure in Patients with Chronic Hepatitis B Virus Infection Treated with Nucleos(t)ide Analogues: A Real-World Study
por: Caviglia, Gian Paolo, et al.
Publicado: (2021)

A Review of HDV Infection
por: Caviglia, Gian Paolo, et al.
Publicado: (2022)

Microscopic colitis in patients with mild duodenal damage: A new clinical and pathological entity (“lymphocytic enterocolitis”)?
por: Bonagura, Gabriele Antonio, et al.
Publicado: (2016)

The Usefulness of Microencapsulated Sodium Butyrate Add-On Therapy in Maintaining Remission in Patients with Ulcerative Colitis: A Prospective Observational Study
por: Vernero, Marta, et al.
Publicado: (2020)

Risk Factors for Liver Decompensation and HCC in HCV-Cirrhotic Patients after DAAs: A Multicenter Prospective Study
por: Morisco, Filomena, et al.
Publicado: (2021)

Switching from Biosimilar to Biosimilar Adalimumab, Including Multiple Switching, in Crohn’s Disease: A Prospective Study
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2021)

Evaluation of Drug Interactions in Patients Treated with DAAs for Hepatitis C Therapy with Comorbidities and Cardiovascular Issues—A Delphi Consensus Project
por: Borghi, Claudio, et al.
Publicado: (2022)

Efficacy of a Preparation Based on Calcium Butyrate, Bifidobacterium bifidum, Bifidobacterium lactis, and Fructooligosaccharides in the Prevention of Relapse in Ulcerative Colitis: A Prospective Observational Study
por: Caviglia, Gian Paolo, et al.
Publicado: (2021)

Inflammatory Bowel Disease Nurse—Practical Messages
por: Rosso, Chiara, et al.
Publicado: (2021)

Predictive Factors of Surgical Recurrence in Patients with Crohn’s Disease on Long-Term Follow-Up: A Focus on Histology
por: Caviglia, Gian Paolo, et al.
Publicado: (2022)

Special Issue “Advances in Gastrointestinal and Liver Disease: From Physiological Mechanisms to Clinical Practice”
por: Caviglia, Gian Paolo, et al.
Publicado: (2022)

Changes in Liver Stiffness and Markers of Liver Synthesis and Portal Hypertension following Hepatitis C Virus Eradication in Cirrhotic Individuals
por: Armandi, Angelo, et al.
Publicado: (2022)

Endoscopic ultrasound to diagnose pneumatosis cystoides intestinalis (with video)
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2017)

Local Tumor Progression of Hepatocellular Carcinoma After Microwave Percutaneous Ablation: A Preliminary Report
por: Brunello, Franco, et al.
Publicado: (2012)

Adalimumab Therapy Improves Intestinal Dysbiosis in Crohn’s Disease
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2019)

Baseline and Breakthrough Resistance Mutations in HCV Patients Failing DAAs
por: Paolucci, Stefania, et al.
Publicado: (2017)

The hepatitis D virus in Italy. A vanishing infection, not yet a vanished disease
por: Caviglia, Gian Paolo, et al.
Publicado: (2021)

Serum Interleukin-6 and -8 as Predictors of Response to Vedolizumab in Inflammatory Bowel Diseases
por: Bertani, Lorenzo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_nv9s82u5eclc5scbl3g6nfhsgr